European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment -

...

Related Keywords

Boston ,Massachusetts ,United States ,France ,London ,City Of ,United Kingdom ,Australia ,Rome ,Lazio ,Italy ,America ,Reshma Kewalramani ,Franco Locatelli ,European Union ,Catholic University Of The Sacred Heart ,Exchange Commission ,Vertex Pharmaceuticals Incorporated Nasdaq ,Department Of Pediatric Hematology ,European Commission ,Youtube ,Linkedin ,Companies To Work ,Vertex Pharmaceuticals Incorporated ,Chief Executive Officer ,Catholic University ,Sacred Heart ,Pediatric Hematology ,Bambino Ges ,Sickle Cell Disease ,Transfusion Dependent Beta Thalassemia ,Conditional Marketing Authorizations ,North America ,Latin America ,Top Employers ,Private Securities Litigation Reform Act ,Markets ,